The only thing that needs fixing is your attitide. Everything that Mark announced in Dec 14 has happened (except for the 1102 partnership). Sure we would like more detail on the 1103 deal, but non disclosure is common with Bio licensing, so no surprises there. All we need is the 1102 partnership and we are 100% on target.
Ann: ATL1102 Early Access Program for Patients with MS, page-21
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 9.8¢ | $49.85K | 497.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 101000 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 282099 | 4 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |